Europe — EMA
Manidipina Teva (Manidipine Dihydrochloride)
GNH USA supplies Manidipina (Manidipine), a calcium channel blocker indicated for hypertension management. Request a quote for reliable global supply.
Request sourcing
What is Manidipine Dihydrochloride?
Manidipine, the active ingredient in Manidipina Teva, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adults with essential hypertension.
GNH USA supplies Manidipina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Manidipine Dihydrochloride used for?
Manidipine is a calcium‑channel‑blocking antihypertensive that acts on the vascular smooth‑muscle pathway to control high blood pressure.
- Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
What are the side effects of Manidipine Dihydrochloride?
Manidipine is generally well tolerated, but several adverse reactions have been reported.
Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Nausea - Tachycardia
Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Hepatic dysfunction - Allergic reactions including rash - Angioedema - Cardiac arrhythmias
What precautions apply to Manidipine Dihydrochloride?
Manidipine should be used with attention to several safety considerations.
- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Discontinuation: avoid abrupt withdrawal in patients with severe hypertension. - Hepatic impairment: use with caution; dose adjustment may be required. - Renal impairment: monitor renal function, especially in the elderly. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Storage: Store below 25°C: keep in the original pack, protect from moisture.
What does Manidipine Dihydrochloride interact with?
Manidipine may interact with other medicines, altering its efficacy or safety.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Concomitant use with other antihypertensives: risk of additive hypotensive effect.
Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function. - Diuretics: may enhance electrolyte disturbances. - Grapefruit juice: may increase systemic exposure. - Beta‑blockers: may require dose adjustment for heart rate control.
